Drug Type Single-chain FV antibody fragment, Biosimilar |
Synonyms Brolucizumab Eye Drop(Wincal Biopharm), Brolucizumab-dbll Biosimilar (Wincal Biopharm Inc.), 布西珠单抗滴眼液(Wincal Biopharm) |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Age Related Macular Degeneration | Preclinical | United States | 22 May 2023 |






